Regulatory and Washington

Press enter to search
Close search
Open Menu

Regulatory and Washington

Regulatory news and trends in retail pharmacies.

NPA, cbdMD plan virtual regulatory conference

The Regulatory Roadmap for the CBD Industry conference is slated for Oct. 21, with various moderators who will participate in a Q&A with the CEO of The Natural Products Association, Daniel Fabricant.

Trump’s executive order calls for government to ‘buy American’ for essential drugs

Trump’s executive order will require the government to develop a list of essential medicines and medical supplies from U.S. companies to buy.

President Donald Trump issued four executive orders Friday, largely focused on bringing down drug costs, which split the industry in terms of reactions.

The INFORM Consumers Act targets organized retail crime and would shed light on certain sellers by requiring online retailers to verify high-volume sellers.

The Food and Drug Administration has requested that manufacturers withdraw all prescription and OTC ranitidine drugs from the market immediately.

A new bill introduced by Sens. Bill Cassidy, R-La., and Dick Durbin, D-Ill., focused on improving transparency around third-party sellers online, is getting the backing of Walgreens.

Four trade associations representing the dietary supplement industry have joined forces to urge Congress to provide legal clarity regarding the CBD marketplace.

Pharmacy organizations are urging the Senate Finance Committee to swiftly take action on DIR fee reform.

In a letter to the Trump administration, legislators noted that DIR fees on pharmacies participating in Part D grew by 45,000% between 2010 and 2017.

The Council for Responsible Nutrition recently praised two senators and two representatives for their work to introduce the SNAP Vitamin and Mineral Improvement Act

Among organizations and companies sharing their thoughts about cannabis and cannabis-derived products were the Food Marketing Institue, the National Cannabis Industry Association and manufacturer Functional Remedies.

SILVER SPRING, Md. — The Food and Drug Administration has approved a new drug for epilepsy, the agency said Monday.

The FDA announced the approval of Eisai's Fycompa (perampanel) tablets to treat partial-onset seizures in patients ages 12 years and older. Partial seizures are the most common type seen in people with epilepsy, according to the FDA.

NEW YORK – Watson Pharmaceuticals and Actavis will have to divest rights to almost two dozen drugs as a condition for U.S. regulatory approval of their $5.6 billion merger announced earlier this year, according to regulatory documents.

SWIFTWATER, Pa. — Sanofi Pasteur announced Monday the presentation of three clinical trials of an experimental influenza vaccine.

Show More